Synthesis and Optimization of Novel 4,4-Disubstituted Cyclohexylbenzamide Derivatives as Potent 11beta-HSD1 Inhibitors
Sun, D., Wang, Z., Caille, S., DeGraffenreid, M., Gonzalez-Lopez de Turiso, F., Hungate, R., Jaen, J.C., Jiang, B., Julian, L.D., Kelly, R., McMinn, D.L., Kaizerman, J., Rew, Y., Sudom, A., Tu, H., Ursu, S., Walker, N., Willcockson, M., Yan, X., Ye, Q., Powers, J.P.(2011) Bioorg Med Chem Lett 21: 405-410
- PubMed: 21093258 
- DOI: https://doi.org/10.1016/j.bmcl.2010.10.129
- Primary Citation of Related Structures:  
3PDJ - PubMed Abstract: 
The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models.
Organizational Affiliation: 
Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. daqings@amgen.com